Core Insights - Radiopharm Theranostics has initiated its first-in-human Phase 1 clinical trial of RAD 402, a monoclonal antibody targeting KLK3 for advanced prostate cancer [1][3] - The trial aims to evaluate the safety, tolerability, and preliminary clinical activity of RAD 402, with a focus on determining the Maximum Tolerated Dose (MTD) and/or recommended phase 2 dose (RP2D) [2] Group 1: Product Development - RAD 402 is designed to selectively target KLK3-expressing tumors while minimizing off-target exposure, demonstrating strong tumor uptake and minimal bone or marrow involvement in preclinical studies [3][4] - The preclinical proof-of-concept studies showed a hepatic excretion profile consistent with expectations for a monoclonal antibody, indicating a favorable biodistribution [4] Group 2: Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [5] - The company has a diverse pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors, including lung, breast, prostate, and brain metastases [5]

Core Insights - The interim analysis of RAD 101 shows that 90% of patients achieved concordance between PET imaging and MRI, indicating strong diagnostic potential for brain metastases [1][2][4] - The first five patients with six-month follow-up data exhibit a positive trend in sensitivity and specificity, which are critical for diagnostic accuracy [3][4] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals to address high unmet medical needs [1][11] - The company is listed on ASX (RAD) and NASDAQ (RADX), with a pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumor cancers [11] Clinical Trial Details - The U.S. Phase 2b clinical trial of RAD 101 involves 30 patients with confirmed recurrent brain metastases, aiming to evaluate the diagnostic performance of the imaging agent [9] - The primary objective is to assess concordance between RAD 101 positive lesions and those identified through conventional MRI [9] Product Information - RAD 101 is a novel imaging agent targeting fatty acid synthase (FASN), which is overexpressed in many solid tumors, including brain metastases [10] - The imaging agent has received FDA Fast Track Designation to differentiate between recurrent disease and treatment effects in brain metastases [4] Market Context - In the U.S., over 300,000 patients are diagnosed annually with cerebral metastases, and the incidence of Intracranial Metastatic Disease (IMD) is increasing due to advancements in systemic therapy [5] - Current imaging methods, such as contrast-enhanced MRI, have limitations, particularly in follow-up scans, highlighting the need for improved diagnostic tools like RAD 101 [5]

Core Insights - The first patient has been dosed in the First-In-Human Phase 1/2a clinical trial of 177Lu-BetaBart (RV-01), marking a significant milestone for the company as it is the first radiotherapeutic agent from their joint venture to enter clinical trials [1][4] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [7] - The company has a pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors, including lung, breast, and brain metastases [7] Product Details - 177Lu-BetaBart is a Lu-tagged engineered monoclonal antibody with a strong affinity for the 4Ig isoform of B7-H3, an immune checkpoint molecule overexpressed in several tumor types, making it a promising target for antibody-based cancer immunotherapy [3][5] - Preclinical studies have shown that RV-01 can induce tumor shrinkage and prolong survival in treated animals, supporting its potential use in multiple indications such as prostate, pancreatic, and breast cancers [5][6] Clinical Trial Information - The Phase 1/2a clinical trial is designed to evaluate the safety, biodistribution, radiation dosimetry, and preliminary anti-tumor activity of 177Lu-BetaBart, with plans to enroll 61 participants with various types of advanced solid tumors [2][6] - The trial aims to establish the recommended dose for future studies, further validating the therapeutic potential of 177Lu-BetaBart [2]

Core Insights - The interim results from the Phase 2b clinical trial of RAD 101 indicate that 92% of evaluable participants met the primary endpoint of MRI concordance in patients with brain metastases [1][5] - The company has approximately $34.52 million in cash and cash equivalents, providing a financial runway into 2027 to advance its pipeline of radiotherapeutic programs [1][19] - The CEO emphasized a focus on advancing radiopharmaceutical assets and delivering meaningful data across multiple programs in 2026 [2] Clinical Pipeline Updates - RAD 101 is currently in a Phase 2b clinical trial for patients with recurrent brain metastases, with enrollment expected to complete in Q1 2026 [3] - RAD 202 is being evaluated in a Phase 1 'HEAT' clinical trial for HER2-positive advanced solid tumors, with a recent recommendation to escalate dosing to 75mCi [4][6] - RAD 204 is in a Phase 1 study for PD-L1-driven cancers, with initial data showing stable disease in 2 out of 3 patients for 5.5 months, compared to 3.5 months with standard care [12] Financial Performance - The company reported a net cash outflow of $22.67 million for the six months ending December 31, 2025, with a cash balance increase from $29.12 million to $34.52 million [19] - In October 2025, the company secured commitments to raise approximately $35 million through a private placement [19] Strategic Developments - The company increased its ownership in Radiopharm Ventures from 75% to 87.5%, indicating progress in its cancer therapeutic pipeline [13] - RAD 402 received ethics committee approval to initiate a Phase 1 clinical trial for metastatic or locally advanced prostate cancer, expected to start in Q1 2026 [14]

Core Insights - Radiopharm Theranostics has increased its ownership stake in Radiopharm Ventures, LLC from 75% to 87.5% as the joint venture progresses in its cancer therapeutic pipeline [1][2] Group 1: Joint Venture and Ownership - The increase in ownership percentage reflects the promising progress of the joint venture, particularly with the B7H3 candidate and other preclinical assets [2] - Radiopharm Ventures, LLC was launched in September 2022 in collaboration with The University of Texas MD Anderson Cancer Center to develop novel radiopharmaceutical products for cancer treatment [5] Group 2: Product Development and Clinical Trials - The lead candidate, Betabart (RV01), is a monoclonal antibody targeting B7H3, which has received Investigational New Drug clearance from the U.S. FDA and is expected to begin dosing the first patient in Q1 2026 [3][7] - Two additional preclinical candidates have shown early positive results and are moving towards final candidate selection, with applications across multiple solid tumor types [4][7] Group 3: Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, with a pipeline that includes one Phase 2 and four Phase 1 trials in various solid tumor cancers [6]

Core Insights - The interim analysis of RAD 101 shows that 92% of evaluable patients achieved concordance with MRI imaging, indicating significant tumor uptake in brain metastases [1][2] - The company plans to initiate a pivotal study by the end of 2026, bolstered by the positive interim data from the Phase 2b trial [3] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [1][10] - The company is listed on ASX (RAD) and NASDAQ (RADX) and has a pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors [10] Clinical Trial Details - The Phase 2b clinical trial is evaluating the diagnostic performance of RAD 101 in 30 individuals with confirmed recurrent brain metastases from solid tumors [8] - The primary objective is to assess concordance between RAD 101 positive lesions and those seen in conventional MRI imaging [8] Market Opportunity - The U.S. market opportunity for RAD 101 is estimated to exceed $500 million annually, positioning it among the top three imaging agents in the market [3] - Over 300,000 patients are diagnosed with brain metastases annually in the U.S., highlighting a significant patient population for RAD 101 [4][3] Technology and Innovation - RAD 101 is a novel imaging agent targeting fatty acid synthase (FASN), which is overexpressed in many solid tumors, including brain metastases [9] - The integration of RAD 101 PET with standard MRI could enhance patient management and treatment decisions for brain metastases [3]

Core Insights - Radiopharm Theranostics has received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia to initiate a First-In-Human (FIH) Phase 1 clinical trial for RAD 402, a radiotherapeutic targeting KLK3 for metastatic or locally advanced prostate cancer [1][4] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs, listed on ASX (RAD) and NASDAQ (RADX) [5] - The company has a diverse pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors, including lung, breast, and brain metastases [5] Product Details - RAD 402 is an anti-KLK3 monoclonal antibody radiolabelled with the radionuclide 161Tb, designed for the treatment of prostate cancer, with KLK3 being a key biomarker for the disease [2] - Preclinical studies have demonstrated strong tumor targeting and a favorable excretion profile for RAD 402, supporting its potential effectiveness [3] Clinical Development - The initiation of the Phase 1 trial for RAD 402 is significant as it is reportedly the first company-sponsored therapeutic trial utilizing 161Tb, highlighting the innovative approach of targeting KLK3 in advanced prostate cancer [4]

Core Insights - The Phase 2b clinical trial for RAD101 has reached a 50% patient enrollment milestone, indicating progress towards demonstrating its clinical benefits in differentiating tumor recurrence from radiation necrosis in brain metastasis patients [2][6] - Early patient data shows significant and selective tumor uptake in brain metastases, aligning with previous Phase 2a results, which may lead to a global Phase 3 registrational trial if confirmed [3][7] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [1][9] - The company is listed on ASX (RAD) and NASDAQ (RADX), with a pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumor cancers, including lung, breast, and brain metastases [9] Clinical Trial Details - The Phase 2b trial is a multicenter, open-label study evaluating the diagnostic performance of 18F-RAD101 in 30 individuals with confirmed recurrent brain metastases from solid tumors [6] - The primary objective is to assess the concordance between 18F-RAD101 positive lesions and those identified through conventional imaging methods [6] Product Information - RAD101 is a novel imaging small molecule targeting fatty acid synthase (FASN), which is overexpressed in many solid tumors, including brain metastases [2][7] - The product has received FDA Fast Track Designation to help distinguish between recurrent disease and treatment effects in brain metastases [5]

Core Insights - Radiopharm Theranostics has completed enrollment for the second cohort in the Phase 1 trial of 177Lu-RAD204, which targets PD-L1 positive advanced cancers, marking a significant milestone for the company [1][2] - The Data and Safety Monitoring Committee has approved advancing to a higher dose of 90mCi for the third cohort of patients [2] - The trial aims to evaluate the safety, tolerability, biodistribution, radiation dosimetry, and preliminary anti-tumor activities of 177Lu-RAD204 in patients with metastatic solid tumors [2][3] Company Overview - Radiopharm Theranostics is a clinical-stage biopharmaceutical company focused on developing innovative oncology radiopharmaceuticals for high unmet medical needs [1][5] - The company is listed on both ASX (RAD) and NASDAQ (RADX) and has a diverse pipeline that includes one Phase 2 and four Phase 1 trials targeting various solid tumors [5] - The company’s technology platform spans peptides, small molecules, and monoclonal antibodies for cancer treatment [5] Product Details - 177Lu-RAD204 is a single-domain monoclonal antibody that targets PD-L1, which is overexpressed in many solid tumors, making it a promising therapeutic target [3][4] - Previous Phase 1 imaging data indicated that the diagnostic compound is safe and has acceptable dosimetry in NSCLC patients [3]

Core Insights - Radiopharm Theranostics is advancing its clinical programs with promising early data from multiple trials, indicating strong potential for its radiopharmaceutical pipeline [1][2][3] Clinical Trials and Data - Preliminary data from the Phase 2b trial of RAD 101 shows uptake in brain metastases from solid tumors, with topline results expected by H1 2026 [1][6] - The Phase 1 trial of RAD 202 (HER2) has shown higher than expected tumor uptake, with data from the second cohort anticipated by year-end 2025 [1][10] - RAD 204 (PD-L1) has demonstrated promising tumor uptake and stable disease in two out of three patients at the first dose level [5][11] - RAD 301 is being evaluated in a Phase 1 imaging trial for pancreatic cancer, with initial data supporting a move to a Phase 2 trial [8][12] Regulatory and Designation Updates - RAD 101 has received FDA Fast Track Designation to expedite its review process for patients with cerebral metastases [3] - RAD 301 has received Orphan Drug Designation from the FDA, highlighting its potential in treating pancreatic ductal adenocarcinoma [8] Company Strategy and Future Plans - The company plans to initiate Phase 1 trials for RV01 and RAD402 by year-end 2025, expanding its clinical portfolio to include four therapeutic candidates and two imaging agents [2] - The strategic execution of the company remains strong, with a focus on advancing multiple trials and achieving significant milestones [2][9]